Feuth Thijs, Rajalahti Iiris, Vasankari Tuula, Gissler Mika, Rimhanen-Finne Ruska, Finne Patrik, Helanterä Ilkka
Department of Pulmonary Diseases and Allergology, Turku University Hospital, Turku, Finland.
Department of Pulmonary Medicine and Allergology, Faculty of Medicine, University of Turku, Turku, Finland.
Transplant Direct. 2023 Aug 24;9(9):e1527. doi: 10.1097/TXD.0000000000001527. eCollection 2023 Sep.
World Health Organization recommends tuberculosis (TB) preventive treatment for risk groups such as patients preparing for organ transplantation. Pretransplant screening or treatment of latent TB infection has not been routine practice in Finland.
In this nationwide registry study, we assessed the risk of TB among kidney transplant recipients compared to the general population. TB cases were identified by data linkage of the national infectious disease and the national transplant registries between 1995 and 2019. Standardized incidence ratios were calculated with adjustment for age, sex, and annual TB dynamics.
A total of 4101 kidney transplants in 3900 recipients with a follow-up of 37 652 patient-years were included. Eighteen TB cases were detected. Patients diagnosed with TB were older (median age 64 y, interquartile range 56-66) at transplantation than those without TB (median 51 y, interquartile range 41-60, < 0.001). The standardized incidence ratio of TB was 6.9 among kidney transplant recipients compared to general population during the whole study period 1995-2019 but decreased from 12.5 in 1995-2007 to 3.2 in 2008-2019. The standardized incidence ratio was 44.2 during the first year after transplantation. Significant differences in 5-y graft losses were not detected between TB patients and those without TB.
The standardized incidence ratio of TB in kidney transplant recipients has decreased over the years, but these patients remain at risk of TB, especially during the first posttransplant year. Cost-benefit analysis is required to address feasibility of latent TB infection screening among transplant candidates in countries with low incidence of TB.
世界卫生组织建议对器官移植准备患者等风险群体进行结核病(TB)预防性治疗。芬兰尚未将移植前潜伏性结核感染的筛查或治疗作为常规做法。
在这项全国性登记研究中,我们评估了肾移植受者与普通人群相比患结核病的风险。通过1995年至2019年国家传染病登记和国家移植登记的数据关联确定结核病病例。计算标准化发病率,并对年龄、性别和年度结核病动态进行调整。
共纳入3900名接受者的4101例肾移植,随访37652患者年。检测到18例结核病病例。诊断为结核病的患者移植时年龄(中位年龄64岁,四分位间距56 - 66岁)比未患结核病的患者(中位年龄51岁,四分位间距41 - 60岁,<0.001)大。1995 - 2019年整个研究期间,肾移植受者结核病的标准化发病率为6.9,但从1995 - 2007年的12.5降至2008 - 2019年的3.2。移植后第一年标准化发病率为44.2。结核病患者和未患结核病患者之间未检测到5年移植肾丢失的显著差异。
多年来肾移植受者结核病的标准化发病率有所下降,但这些患者仍有患结核病的风险,尤其是在移植后的第一年。在结核病发病率低的国家,需要进行成本效益分析以探讨对移植候选者进行潜伏性结核感染筛查的可行性。